PMID- 33900803
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Linking)
VI  - 17
IP  - 7
DP  - 2021 Jul
TI  - Impact of Oral Chemotherapy Management Program on Capecitabine Toxicity 
      Management.
PG  - e1021-e1029
LID - 10.1200/OP.20.00947 [doi]
AB  - PURPOSE: Increasing use of oral chemotherapy has created unique challenges 
      related to patient safety and compliance. To address this issue, the Henry Ford 
      Cancer Institute at Henry Ford Health System developed and implemented a 
      system-wide, multidisciplinary program named the Oral Chemotherapy Management 
      Program (OCMP). The purpose of this study was to evaluate the impact of OCMP on 
      patient outcomes in those receiving capecitabine. METHODS: This was a 
      retrospective, quasi-experimental study that compared outcomes in patients 
      receiving capecitabine before and after OCMP implementation. The co-primary 
      outcomes were incidence(s) of grade 1-4 and grade 3-4 adverse effects (AEs) 
      associated with capecitabine. Secondary outcomes were emergency department (ED) 
      visits, hospitalizations because of toxicity, and adherence rate. RESULTS: OCMP 
      patients had significantly lower overall incidence of AE of any grade (58.9% v 
      70.3%; 95% CI, 0.39 to 0.94; P = .03). OCMP implementation significantly lowered 
      incidence of any grade and grade 3-4 nausea, vomiting, and/or diarrhea, and grade 
      3-4 hand-foot syndrome. It resulted in the decreased number of ED visits (8.9% v 
      18.9%; P = .005) and hospitalizations (6.3% v 17.1%; P = .002), as well as 
      improved medication adherence rates (0.94 v 0.97; P = .03). CONCLUSION: Most 
      patients who developed capecitabine-related AE required intervention by OCMP. 
      Implementation of OCMP reduced the incidence of high-grade AE, decreased the 
      number of ED visits and hospitalizations because of AE, and improved the 
      medication adherence rate.
FAU - Nhean, Salin
AU  - Nhean S
AD  - Correct Rx Pharmacy Services, Hanover, MD.
AD  - Henry Ford Cancer Institute, Detroit, MI.
FAU - Kostoff, Diana
AU  - Kostoff D
AUID- ORCID: 0000-0002-9376-4928
AD  - Henry Ford Cancer Institute, Detroit, MI.
FAU - Yang, Jessica J
AU  - Yang JJ
AUID- ORCID: 0000-0001-9713-0589
AD  - Henry Ford Cancer Institute, Detroit, MI.
FAU - Vogel, Vishnuprabha
AU  - Vogel V
AD  - Henry Ford Cancer Institute, Detroit, MI.
FAU - Rybkin, Igor I
AU  - Rybkin II
AUID- ORCID: 0000-0002-8434-1093
AD  - Henry Ford Cancer Institute, Detroit, MI.
LA  - eng
PT  - Journal Article
DEP - 20210426
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
RN  - 0 (Antineoplastic Agents)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Administration, Oral
MH  - *Antineoplastic Agents/adverse effects
MH  - Capecitabine/adverse effects
MH  - *Hand-Foot Syndrome/drug therapy
MH  - Humans
MH  - Retrospective Studies
COIS- Diana KostoffResearch Funding: Pfizer Igor I. RybkinConsulting or Advisory Role: 
      AstraZenecaNo other potential conflicts of interest were reported.
EDAT- 2021/04/27 06:00
MHDA- 2021/08/12 06:00
CRDT- 2021/04/26 17:11
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2021/04/26 17:11 [entrez]
AID - 10.1200/OP.20.00947 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2021 Jul;17(7):e1021-e1029. doi: 10.1200/OP.20.00947. Epub 2021 
      Apr 26.